Private equity firm TPG is exploring a sale of Immucor, the maker of tests that screen blood before transfusions and organ transplants.
TPG is working with an adviser on potential options for the company it took private about a decade ago, the people said, asking not to be identified because the information isn’t public. Some private equity firms and companies have expressed preliminary interest, the people said.
The diagnostic equipment manufacturer could fetch more than $2bn in a sale, the people said. While deliberations are ongoing, discussions remain at an early stage and TPG could opt to keep the company longer.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
A representative for TPG declined to comment. Immucor couldn’t be immediately reached for comment.
In July 2011, Immucor agreed to go private and sell itself to TPG for $1.97bn. Since then the Georgia-based company has made multiple add-on acquisitions including Sentilus Inc. and Organ-i Inc.
Immucor makes reagents, instruments and other products used to screen blood. Laboratories also use its products to run tests before and after organ transplants.
Source: Yahoo Finance
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...